News & Events
-
March 29, 2023
C-Path Appoints Key Scientific Leaders to Executive Roles
TUCSON, Ariz., March 29, 2023 — Critical Path Institute (C-Path) announced today the appointment of three accomplished leaders to key executive roles within the organization. Cheryl D. Coon, Ph.D., joins C-Path as the Vice President for the Clinical Outcome Assessment (COA) Program. Shu Chin Ma, Ph.D., M.Sc., M.Phil., EMBA, has been named Vice President of...... - March 21, 2022
-
February 23, 2022
Recommendations to Optimize the Use of Volumetric MRI in Huntington’s Disease in Clinical Trials
C-Path’s Huntington’s Disease Regulatory Science Consortium (HD-RSC) has published a new paper on volumetric MRI-based biomarkers in HD. The manuscript is a companion to a recent manuscript that summarized published evidence of regional brain volume losses in HD, cross-sectional correlations between regional brain volumes and disease characteristics, longitudinal change characteristics of the volumetric measures, and...... -
September 29, 2021
Volumetric MRI-Based Biomarkers in Huntington’s Disease: An Evidentiary Review
C-Path’s Huntington’s Disease Regulatory Science Consortium (HD-RSC) has published a new paper on volumetric MRI-based biomarkers in HD.
-
May 17, 2018
New Collaboration Seeks to Speed Huntington’s Disease Drug Licensing
This article originally appeared on HDBuzz and is reprinted here under Creative Commons license. Critical Path Institute launches new initiative to get HD drugs licensed as quickly as possible By Dr Jeff Carroll, Edited by Dr Ed Wild Originally published here on May 09, 2018 Recently the Critical Path Institute announced a new effort – the Huntington’s Disease......